The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier. Our core portfolio currently consists of six programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients by directly addressing a cause or risk factor for the disease.
In developing our programs, we rigorously follow three principles
Each program is addressing a target or pathway that is genetically validated to cause or increase the risk for neurodegenerative diseases.
Each product candidate is designed to optimize therapeutic exposure in the brain.
The development path of each program is enabled by biomarkers to monitor early effects of the drug and select the right patients and the right dose in clinical development.
© 2017 Denali Therapeutics Inc. | 151 Oyster Point Blvd – South San Francisco, CA 94080 | contact@dnli.com
Privacy Policy | Terms of Use
